We showed how this BsAb potently neutralized signaling from TSLP, IL-4, and IL-13; reduced inflammatory responses in human cell-based assays; and provided broader efficacy in a TSLP/OVA-induced asthma model compared with single-pathway blockade. This evidence concerns the gene IL4 and asthma.